Complications of neuroleptic hyperprolactinaemia
https://doi.org/10.31363/2313-7053-2018-2-104-108
Abstract
Te article provides an overview of foreign and domestic literature on the development of complications associated with neuroleptic hyperprolactinaemia in patients with schizophrenia in the course of prolonged antiretroviral therapy with antipsychotics. Most researchers agree that long-term neuroleptic hyperprolactinemia signifcantly impairs the physical health of patients with mental disorders. Timely diagnosis and correction of this side effect of psychopharmacotherapy will signifcantly reduce the risk of complications and improve the social functioning of patients with schizophrenic disorders.
About the Authors
G. E. Mazo
V. M. Bekhterev National Research Medical Center For Psychiatry And Neurology Of Te Russian Federation Ministry Of Health, St.Petersburg
Russian Federation
Russian Federation
L. N. Gorobets
Moscow Research Institute of Psychiatry — branch of V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow
Russian Federation
Russian Federation
References
1. Горобец Л.Н., Поляковская Т.П., Литвинов А.В., Василенко Л.М., Буланов В.С. Проблема остеопороза у больных с психическими расстройствами при нейролептической терапии. Часть I // Социальная и клиническая психиатрия.—Том 22.—Выпуск 3.—2012.—С. 107-112.
2. Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии: клиника, диагностика, факторы риска и коррекция // Журнал неврологии и психиатрии имени С.С.Корсакова. — 2014. — Том 114, №10. — С. 122-130.
3. Горобец Л.Н., Мазо Г.Э. Гиперпролактинемия при использовании антипсихотиков второго поколения: принципы профилактики, диагностики и коррекции // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. — 2017. — №1. — С. 63-70.
4. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. — М.: Триада-Х. — 2004.
5. Курляндская Р.И. Влияние гиперпролактинемии на основные показатели жирового обмена/ Р.И.Курляндская, Т.И.Романцова // Леч. врач. — 2004. — №1. — С. 6-9.
6. Мазо Г.Э. Перспективы развития эндокринологической психиатрии / Современные достижения в диагностике и лечении эндогенных расстройств. Сборник научных трудов. Серия «Современная психоневрология». СанктПетербург, 2008. С. 210-224.
7. Пирматова М.А., Анварова Ш.С., Ниязова Н.Ф. К вопросу о нарушении жиро-углеводного обмена у больных с синдромом гиперпролактинемии // Международный научно-исследовательский журнал. Медицинские науки.—2016.—№ 7 (49), часть 3.—С. 85-90.
8. Чуршин А.Д. Клинико-функциональные и метаболические характеристики ишемической болезни сердца у женщин и дифференцированная терапия. Дисс. … докт. мед. наук. 2009.
9. Bushe C., Shaw M., Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia. — J. Psy- chopharmacol. — 2008. — Vol.22. — P.46-55.
10. Bushe C., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? // Ann. Clin. Biochem. — 2010. — Vol. 47. — Р.292-300.
11. BusheC., Hodgson R. Schizophrenia and cancer: in 2010 do we understand the connection? — Can. J. Psychiatry. — 2010. — Vol.55. — P. 761-767.
12. Catts V.S., Catts S.V., O’Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their frst-degree relatives−a meta-analysis. — Acta Psychiatr. Scand. — 2008. — Vol.117. — P. 323-336.
13. Cookson J., Hodgson R., Hiram J.W. Prolactin, hyperpro- lactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. — J. Psychopharmacol. — 2012. — Vol.26. — P.42-51.
14. De Bellis A., Bizzarro A., Pivonello R., Lombardi G., Bellastella A. Prolactin and autoimmunity. — Pituitary. — 2005. — Vol.8. — P.25-30.
15. DeHert M., Peuskens J., Sabbe T. et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. — Acta Psychiatr. Scand. — 2016. — Vol.133. — P.5-22.
16. Dorshkind K., Horseman N.. Te roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor defciency. — Endocr. Rev. — 2000. — Vol.21. — P.292-312.
17. Fan Z., Wu Y.,Shen J., Ji T., Zhan R. Schizophrenia and the risk of cardiovascular diseases:a meta-analysis of thirteen cohort studies. — J Psychiatr Res. — 2013. — Vol.47. — P.1549-1556.
18. Fahy U., Hopton M.I., Hartog M., Bolton C.H., Hull M.G. Te lipoprotein profle of women with hyperprolactinaemic amenorrhoea // Hum. Reprod. - 1999. — Vol.14. — P.285-287.
19. Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function and regulation of secretion. — Physiol Rev. — 2000. — Vol.80. — P.1523- 1631.
20. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation // CNS Drugs. — 2007. — Vol.21, № 8. — Р.641-657.
21. Henry J.F., Sherwin B.B. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. — Behav. Neurosci. — 2012. — Vol.126. — P.73-85.
22. Hofauer L.C., Hamann Ch., Ebeling P.R. Approach to the patient with secondary osteoporosis // Eur. J. Endocrinol. — 2010. — Vol.162. — Р.1009 — 1020.
23. Holt R.I., Hanley N.A. Summary of the regulation and effects of prolactin. In Chapter 5: Te hypothalamus and pituitary gland. — Essential Endocrinology: Blackwell Publishing. — 2006. -66p.
24. Howard L., Kirkwood G., Leesem O. Risk of hip fracture in patients with a history of schizophrenia // Te British Journal of Psychiatry. — 2007. — Vol.190. — Р.129 — 134.
25. Hummer M., Malik P., Gasser R.W. et al. Osteoporosis in patients with schizophrenia//Am J Psychiatry. — 2005. — Vol.162, № 1. — Р.162-167.
26. Ignacak A., Kasztelnik M., Sliwa T., Korbut R., Rajda K., Guzik T. Prolactin not only lactotrophin. A ‘‘new’’ view of the ‘‘old’’ hormone. — J. Physiol. Pharmacol. — 2012. — Vol.63. — P.435-443.
27. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. — Aust. NZ — J. Psychiatry. — 2011. — Vol.45. — P.830-837.
28. Jablensky A., Lawrence D. Schizophrenia and cancer: is there a need to invoke a protective gene? — Arch. Gen. Psychiatry. — 2001. — Vol.58. — P.579-580.
29. Laita P., Cifuentes A., Doll A., Llorente C., Cortés I., Parellada M. et al. Antipsychotic-related abnormal involuntary movements and meta-bolic and endocrine side effects in children and adolescents. — J. Child. Adolesc. Psychopharmacol. — 2007. — Vol.17. — P.487-502.
30. Lee Y.H., Bae S.C., Song G.G. Meta-analysis of associations between functional prolactin -1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus. — Clin Rheumatol. - 2015. — Vol.34. — P.683-690. doi: 10.1007/s10067-015-2904-3. Epub 2015 Feb 28.
31. Li M., Fan Y.L., Tang Z.Y., Cheng X.S. Schizophrenia and risk of stroke: a meta-analysis of cohort studies.—Int. J. Cardiol.—2014.—Vol.173.—P.588-590.
32. Matsuda M., Mori T., Sassa S. et al. Chronic effect of hyperprolactinemia on blood glucose and lipid levels in mice // Life Sciences. — 1996. - Vol.58. – Р.1171-1177.
33. Meaney A.M., Smith S., Howes O.D. et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia // Br. J.Psychiatry. — 2004. — Vol.184. — Р.503–508.
34. Melmed S, Casanueva FF, Hoffman RA, Kleinberg LD, Montori MV, Schlechte AJ, et al., Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. — J. Clin. Endocrinol. Metab. — 2011. — Vol.96. — P.273-288.
35. Misra M., Papakostas G. I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism // Journal of Clinical Psychiatry.—2004.—Vol. 65. –Р.1607-1618.
36. Moffat S.D., Zonderman A.B., Metter E.J., Blackman M.R., Harman S.M., Resnick S.M. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. — J. Clin. Endocrinol. Metab. — 2002. — Vol.87. — P.5001-5007.
37. Moffat S.D., Zonderman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M. et al. Free testosterone and risk for Alzheimer disease in older men. — Neurology. — 2004. — Vol.62. — P.188-193.
38. Morris A. Diabetes: linking diabetes and schizophrenia. — Nat. Rev. Endocrinol. — 2017. — Vol.13. — P. 126.
39. O’Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? — J. Clin. Psychopharmacol. — 2005. — Vol.25. — P.26-31.
40. O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia //J.Psychopharmacol. — 2008. — Vol.22. — Р.70-75.
41. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases // Autoimmun. Rev. — 2007. — Vol.6. — P.537-542.
42. Orbetzova MM1, Kamenov ZA, Kolarov GB, Orbetzova VT, Genchev GD, Genov NS, Zacharieva SZ. Metabolic disturbances in women with polycystic ovary syndrome. — Folia Med (Plovdiv). – 2003. — Vol.45. — P.12-20.
43. Seeman M.V. Women at Greater Risk Tan Men //Schizophr Bull. — 2009. — Vol.35. — Р.937 — 948.
44. Seriwatanachai D., Krishnamra N., van Leeuwen J.P. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization // J. Cell. Biochem. — 2009. — 107. — Р.677- 685.
45. Takkouche B., Montes-Martinez A., Gill S.S. et al. Psychotropic medications and the risk of fractures: a meta-analysis // Drug. Saf. — 2007. — Vol.30. — P. 171–184.
46. Vancampfort D., Correll C.U., Galling B. et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis // World Psychiatry. — 2016. — Vol.15. — P. 166-174.
47. Wang M. et al. Circulating prolactin associates with diabetes and impaired glucose regulation // Diabetes Care. — 2013. — Vol.36. — P.1974-1980.
48. Wang M., Wu X., Chai F., Zhang Y., Jiang J. Plasma prolactin and breast cancer risk: a metaanalysis. — Sci Rep. — 2016. — Vol.6. — P.259-298.
49. Zhuo Ch., Triplett P. T. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. — JAMA Psychiatry. - 2018. — Vol.75. — P.363- 369. doi:10.1001/jamapsychiatry.2017.4748.
Review
For citations:
Mazo G.E., Gorobets L.N. Complications of neuroleptic hyperprolactinaemia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2018;(2):104-108. (In Russ.) https://doi.org/10.31363/2313-7053-2018-2-104-108
Views:
725
Email this article 